🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Medpace Holdings, Inc. MEDP R3KPHARMA

Healthcare · Diagnostics & Research · United States
https://www.medpace.com
Company Profile ↓
$590.89
+26.26% 1Y
Mkt Cap$16.49B
P/E34.68
P/B39.39
52W High$620.75
52W Low$393.42
Book Value$15.54
EPS (TTM)$17.04

Company Overview

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 84.7%.

Consistent Profit Growth

Net profit has compounded at 25.4% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 21.6% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 17.7%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.33.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $2.53B (+20.0% YoY); net profit $451.12M.
  • Trailing 12 Months Year-on-year growth — revenue +17.2%, earnings +37.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 21.6%, profit CAGR 25.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:21.56%
1 Year:17.20%

Compounded Profit Growth

5 Years:25.42%
1 Year:37.10%

Stock Price Performance

1 Year:+26.26%
6 Months:+23.48%
3 Months:+29.04%
1 Month:+0.04%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 87% of range
$393.42 $620.75
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)50.35 · Neutral
Price Performance
1M+0.04%
3M+29.04%
6M+23.48%
1Y+26.26%
Valuation vs Sector

P/E of 34.68 is above the sector median of 24.83 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 84.7%.
  • Compounding revenue at 21.6% over 5 years.
  • Profit CAGR of 25.4% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
34.68
Industry PE
24.83
Forward P/E
30.60
PEG Ratio
2.93
Book Value
$15.54
Price to Book
39.39
P/S
6.14
EV/EBITDA
27.38
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
21.56%
Profit 5Y
25.42%
Revenue (YoY)
17.20%
Earnings (YoY)
37.10%

Profitability & Returns

ROCE
84.68%
ROE
-
ROA
20.10%
Profit Margin
17.66%
Op Margin
20.76%
Gross Margin
72.35%
EPS (Latest Qtr)
$4.25
EPS (TTM)
$17.04

Balance Sheet & Liquidity

Debt/Equity
0.33
Quick Ratio
0.66
Current Ratio
0.73
Debt
$144.11M
Total Assets
$2.06B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
19.46%
Chg in Prom Hold
-0.00%
FII / Inst Holding
91.25%
Chg in FII Hold
-0.25%

Financial Snapshot

Enterprise Value
$16.49B
Total Revenue (TTM)
$2.78B
EBITDA
$611.20M
Free Cash Flow
$510.40M
Operating Cash Flow
$752.66M
Shares Outstanding
27.91M
Gross Margin
72.35%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 MEDP Medpace Holdings, Inc. R3KPHARMA 590.89 34.68 $16.49B 0.00% 84.68% - 21.56% 25.42%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue --------106.61M106.22M110.64M112.68M163.08M170.14M179.25M192.12M200.74M214.10M216.24M229.89M230.88M205.00M230.37M259.96M278.29M295.57M330.95M351.21M383.74M434.07M460.87M492.50M511.04M528.10M533.32M558.57M603.31M659.90M706.60M707.33M
Operating Income 6.39M7.87M7.20M-889.00K12.87M14.11M12.62M12.89M15.94M16.28M17.20M15.44M20.12M23.34M26.92M30.67M25.89M35.26M29.99M36.12M35.50M30.13M46.42M47.60M42.45M53.71M64.20M60.24M77.83M86.20M78.39M84.91M104.07M105.15M112.27M113.52M126.33M141.81M141.50M146.82M
Net Income -59.00K95.00K-133.00K-8.58M3.45M4.96M5.04M-21.00K8.45M9.55M9.83M11.29M14.55M16.57M19.30M22.76M19.20M27.45M23.98M29.81M28.95M24.10M41.46M43.31M39.93M48.57M61.31M49.36M66.03M72.89M61.07M70.55M102.59M88.35M96.43M114.59M90.26M111.14M123.87M121.36M
Diluted EPS 0.000.000.00-0.270.110.150.130.000.200.230.250.300.400.450.520.610.510.730.630.780.760.641.091.141.061.291.691.462.052.271.932.223.202.753.013.673.103.864.284.25

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 359.06M421.58M436.15M704.59M860.97M925.92M1.14B1.46B1.89B2.11B2.53B
Operating Income 20.56M52.49M64.86M101.05M127.26M167.04M198.62M278.70M336.82M446.87M534.93M
Net Income -8.67M13.43M39.12M73.19M100.44M145.38M181.85M245.37M282.81M404.39M451.12M
Diluted EPS -0.280.370.981.972.673.844.817.288.8812.6315.28

Balance Sheet (Annual)

Figures in USD.

Metric Mar 2014Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Jan 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --984.04M979.11M950.72M967.93M1.00B1.14B1.39B1.66B1.35B1.66B2.10B1.98B
Total Equity 414.00M401.97M413.47M610.71M509.26M598.86M598.86M726.28M805.78M952.93M386.39M558.95M825.54M459.07M
Cash & Equivalents --14.88M37.10M26.48M23.27M-131.92M277.77M461.30M28.27M245.45M669.44M497.05M
Long Term Debt --377.88M151.27M205.11M79.72M-0------
Total Liabilities --570.57M368.39M447.19M378.23M405.92M416.79M584.90M707.01M966.11M1.10B1.28B1.52B
Current Liabilities --134.02M168.60M192.71M257.03M263.12M343.00M440.11M557.22M803.47M925.13M1.10B1.34B

Cash Flows (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -91.73M97.39M156.58M201.87M258.68M263.33M388.05M433.37M608.82M713.22M
Investing Cash Flow --13.42M-12.24M-16.97M-19.14M-31.21M-31.36M-38.74M-34.63M-28.31M-31.14M
Financing Cash Flow --58.01M-97.83M-141.58M-73.92M-82.28M-44.45M-775.77M-182.64M-154.01M-860.39M
Capital Expenditure -6.46M-13.54M-11.72M-16.02M-17.91M-31.34M-28.27M-36.88M-36.65M-36.55M-31.36M
Free Cash Flow -78.19M85.66M140.56M183.96M227.34M235.06M351.17M396.73M572.27M681.87M
Share Buybacks 00155.58M0098.27M62.10M847.85M144.02M169.87M917.39M

Ratios (Annual)

Figures in %.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------
Operating Margin % 5.7%12.5%14.9%14.3%14.8%18.0%17.4%19.1%17.9%21.2%21.1%
Net Margin % -2.4%3.2%9.0%10.4%11.7%15.7%15.9%16.8%15.0%19.2%17.8%
ROE % -2.1%2.2%7.7%12.2%13.8%18.0%19.1%63.5%50.6%49.0%98.3%
ROCE % 2.4%6.5%8.6%14.2%15.9%17.6%18.0%50.8%46.0%44.9%84.7%

Shareholding Pattern

Insiders
19.46%
Institutions
91.25%
Public Float
113.30%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.95% 2.50M $1.53B
2 Price (T.Rowe) Associates Inc 7.42% 2.07M $1.27B
3 AQR Capital Management, LLC 4.58% 1.28M $783.13M
4 Vanguard Portfolio Management LLC 4.06% 1.13M $693.99M
5 Vanguard Capital Management LLC 3.68% 1.03M $628.75M
6 State Street Corporation 2.55% 710.89K $435.30M
7 Geode Capital Management, LLC 2.55% 710.47K $435.04M
8 Wasatch Advisors LP 2.28% 636.60K $389.81M
9 Invesco Ltd. 2.08% 579.24K $354.69M
10 BAILLIE GIFFORD & CO 1.70% 473.21K $289.76M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MEDP

Google News Mon, 07 Sep 2026

Medpace (MEDP) Stock May Look Fairly Valued Despite Strong Cash Flow - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxONUJZaXlSOGM4ekJ5VHlVQTd1RG1RSzByakgzQU90cmpUOW93UTNRaXg1QVlKcFhrY2ZjX0xKY2swbDJDbzd1cUhOTEVjNW10S1hMWXphdzRPQ3g1UlNTczVyRVgwcFcyWXBpSExpb1FlLXJvTmRmb25HNkYzbGdydWpCRE40US14SzF4T0…

Google News Mon, 07 Sep 2026

Medpace Holdings, Inc. (MEDP) Stock Analysis: Evaluating the Healthcare Giant’s Growth Potential - directorstalkinterviews.com

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxQVk5TTEhsOHRIOWQtX0tQSFlpeDBMWVkyaWM3Ujg4QVJOX2hoTDJmblowbzhtNFZjQVRaNGRPbnRJdTI5QVRNVC0zWTNzN1NXVDZVQjZ1Qng2X3pJRnVrdmtyQnZjdmsyTXdHV21yaHJHRWJzYzFQNVp6RWxTMVVuZlhuYWY2b0xSRnJDWU…

Google News hu, 23 Jul 2026

Why Is Medpace (MEDP) Stock Soaring Today - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPcTVIZUdLZTBaandObXFra1FNRUJMcTlOT2ZvRm0zVktwLUxWMWRBTVNwZEd3UUVOZ0NvVkJiUEtsZ2NObzZmeFYwd0xSc0xYSXJhdXdHMEVlcjVnNVc1cXlCT0RtYW9neHNGQWJtWmt4UGNSbGhOOE9oUVR1aGM1TzZyUXcwakIwR1pMV1…

Google News hu, 27 Aug 2026

Insider Sale: President & CEO of $MEDP Sells 673 Shares - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNSTNrdjItOEdqUG1KMlBkaVo0YmJLX3BTOG4yYzg2bjhvZGwzbWlhYlVNNWZ2bGtMZFR2S2ZKMFQyM1JXbEd3b05zZXVYYTJET1NoQWwyM3RuVE81TTJycksyNWJNZ0tvSFd6OTZ1Yk5DXzRlakVucnFJTTZxejlLT0tMd1M3d3NWbVNQTl…

Google News Fri, 28 Aug 2026

Medpace Holdings (MEDP) director exercises options, sells 3,858 shares - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQRFo4S194X0I2VUNrRHpqb0ZiSXBpV1VJRzB1ZFI4QVJSSmE0VzJJWmVLX1FsMXBHdEVmRzFFN1pHakJHOVZ1NG14QjFNVmpIY1BSNWhqaXg2SjZpODZjRjloNVVkQnBKLThjU1FJMDhKSlA3X09tVGVJUVpvcC1LTGlaQ0o2RTh5T2F5SX…

Google News ue, 01 Sep 2026

Why Medpace (MEDP) is a Top Growth Stock for the Long-Term - Eastern Progress

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNLWRQOGVRazNHNUE2ZmFJcU85eEJVcXBIaXZKcWVWaU1EelFWbEZ2THNDVW41UExCQW9zQ2pDbXFNOUVoOU4zemFxLU1icjU0N0JLbjhEczdROWhDRWVRV0N4RzRsZEhQbThDT2VUUFZJNTNhQXFiRFhiaThiVE5pdWNCNE1tV0wwdk9JLX…

MEDP — Frequently Asked Questions

What is the current share price of Medpace Holdings, Inc. (MEDP)?

As of 2026-09-19 21:16 PDT, Medpace Holdings, Inc. (MEDP) trades at $590.89 on NasdaqGS. Its 52-week range is $393.42 to $620.75.

What is the market capitalisation of MEDP?

Medpace Holdings, Inc. (MEDP) has a market capitalisation of $16.49B on NasdaqGS.

What is the P/E ratio of MEDP?

MEDP trades at a trailing price-to-earnings (P/E) ratio of 34.68. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 39.39.

Is MEDP a good stock to buy?

This page provides a data-driven analysis of Medpace Holdings, Inc. (MEDP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space